Search Results | Clinicalinfo

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 1 – 20 of 3231

Efavirenz / Lamivudine / Tenofovir Disoproxil Fumarate

https://clinicalinfo.hiv.gov/node/11127

https://clinicalinfo.hiv.gov/node/11128

https://clinicalinfo.hiv.gov/node/11128

Guidelines Archive

https://clinicalinfo.hiv.gov/node/11129

Table 20. Common and/or Severe Adverse Effects Associated with Antiretroviral Medications

https://clinicalinfo.hiv.gov/node/11135

Appendix A, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors

https://clinicalinfo.hiv.gov/node/11136

Table 18. Concomitant Use of Selected Antiretroviral Drugs and Hepatitis C Virus Direct-Acting Antiviral Drugs for Treatment of Hepatitis C Virus in Adults With HIV

https://clinicalinfo.hiv.gov/node/11137

Appendix A, Table 5. Characteristics of Protease Inhibitors

https://clinicalinfo.hiv.gov/node/11138

Table 2. Treatment of HIV-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)

https://clinicalinfo.hiv.gov/node/11139

Potential Clinically Relevant Interactions between Antimalarial and Antiretroviral Drugs*

https://clinicalinfo.hiv.gov/node/11142

Dosing Recommendations for Prevention and Treatment of Malaria

https://clinicalinfo.hiv.gov/node/11143

Table 1. Primary Prophylaxis of Opportunistic Infections in Children With and Exposed to HIV— Summary of Recommendations

https://clinicalinfo.hiv.gov/node/11144

Table 2. Secondary Prophylaxis of Opportunistic Infections in Children With and Exposed to HIV — Summary of Recommendations

https://clinicalinfo.hiv.gov/node/11145

Table 3. Treatment of Opportunistic Infections in Children With and Exposed to HIV — Summary of Recommendations

https://clinicalinfo.hiv.gov/node/11146

Table 4. Common Drugs Used for Treatment of Opportunistic Infections in Children With HIV: Preparations and Major Toxicities

https://clinicalinfo.hiv.gov/node/11147

Table 5. HIV-Related Laboratory Monitoring Schedule During Pregnancy

https://clinicalinfo.hiv.gov/node/11148

Table 14. Antiretroviral Drug Use in Pregnancy: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

https://clinicalinfo.hiv.gov/node/11149

Supplemental Table 1. Results of Major Studies on Antiretroviral Interventions to Prevent Perinatal HIV Transmission

https://clinicalinfo.hiv.gov/node/11150

Appendix C. Clinical Trial Efficacy Data for Daily, Oral Tenofovir Disoproxil Fumarate/Emtricitabine as Pre-Exposure Prophylaxis

https://clinicalinfo.hiv.gov/node/11151

https://clinicalinfo.hiv.gov/node/11153